Established in 2003 by preeminent Japanese university researchers, REPROCELL quickly became the leading stem cell research company in Japan. Soon thereafter, REPROCELL products were employed by Professor Shinya Yamanaka (Nobel Laureate, 2012) during his pioneering research on induced pluripotent stem cell (iPSC) technologies at Kyoto University. REPROCELL was the first company to offer iPSC-derived human cardiomyocytes, hepatocytes and neuronal cells for research applications. As a market leader, with a portfolio of cells, culture media and reagents, the company was listed on the Japan JASDAQ / Growth stock market in 2013.
In recent years, many commercial opportunities and applications were developed directly upstream and downstream of the iPSC workflow. Therefore, the company aggressively expanded its busines through a series of acquistions to become the REPROCELL Group Companies. Each company it acquired possessed intellectual property and knowledge that helps to amplify the value of the organization by complementing the capabilities of the others. Together, a workflow has emerged that spans from human tissue acquisition (BioServe®, Biopta®), to iPSC reprogramming (Stemgent®), cell differentiation (REPROCELL), in vitro tissue modelling with 3D technology (Reinnervate®), and assay development for applications in drug discovery (Biopta®). More recently, these companies have been integrated and consolidated to regional offices, and the names converted to product and service brands. In the stem cell and drug discovery “market- space”, no other company has this broad combination of expertise that can be applied to nearly the entire span of the drug discovery pipeline, and even to new areas of regenerative medicine. For a concise summary of REPROCELL's overall capabilities.